Loading...
Loading...
XOMAP| Name | Value |
|---|---|
| Revenues | 1,486.0K |
| Cost of Revenue | 97.0K |
| Gross Profit | 1,389.0K |
| Operating Expense | 7,696.0K |
| Operating I/L | -6,210.0K |
| Other Income/Expense | 219.0K |
| Interest Income | 0.0K |
| Pretax | -5,991.0K |
| Income Tax Expense | -15.0K |
| Net Income/Loss | -5,976.0K |
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring potential future economics associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets, and it helps biotech companies enhance human health by providing financial support and expertise in the development of therapeutic candidates.
